164 related articles for article (PubMed ID: 17546279)
1. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
Polanczyk CA; Wainstein MV; Ribeiro JP
Arq Bras Cardiol; 2007 Apr; 88(4):464-74. PubMed ID: 17546279
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial.
Canoui-Poitrine F; Jeanblanc G; Alberti C; Armoogum P; Cebrian A; Carrié D; Henry P; Teiger E; Slama M; Spaulding C; Durand-Zaleski I
Appl Health Econ Health Policy; 2009; 7(1):19-29. PubMed ID: 19558192
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial.
Rinfret S; Cohen DJ; Tahami Monfared AA; Lelorier J; Mireault J; Schampaert E
Am J Cardiovasc Drugs; 2006; 6(3):159-68. PubMed ID: 16780389
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of drug-eluting stents in Japan.
Ikeda S; Kobayashi M
Keio J Med; 2006 Mar; 55(1):15-22. PubMed ID: 16636645
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of sirolimus-eluting stents.
Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
[TBL] [Abstract][Full Text] [Related]
9. Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.
Stella SF; Gehling Bertoldi E; Polanczyk CA
Med Decis Making; 2016 Nov; 36(8):1034-42. PubMed ID: 26964876
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
11. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial.
van Hout BA; Serruys PW; Lemos PA; van den Brand MJ; van Es GA; Lindeboom WK; Morice MC
Heart; 2005 Apr; 91(4):507-12. PubMed ID: 15772214
[TBL] [Abstract][Full Text] [Related]
12. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
[TBL] [Abstract][Full Text] [Related]
13. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
[TBL] [Abstract][Full Text] [Related]
14. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).
Kaiser C; Brunner-La Rocca HP; Buser PT; Bonetti PO; Osswald S; Linka A; Bernheim A; Zutter A; Zellweger M; Grize L; Pfisterer ME;
Lancet; 2005 Sep 10-16; 366(9489):921-9. PubMed ID: 16154019
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease.
Wisløff T; Atar D; Sønbø Kristiansen I
Am J Ther; 2013; 20(6):596-601. PubMed ID: 21822114
[TBL] [Abstract][Full Text] [Related]
16. [Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system].
Fricke FU; Silber S
Herz; 2005 Jun; 30(4):332-8. PubMed ID: 15965811
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-eluting versus bare-metal stents for the reduction of coronary restenosis: 18-month angiographic results from the GERSHWIN Study.
Brüggenjürgen B; McBride D; Bode C; Hamm CW; Kuck KH; Willich SN
Herz; 2007 Dec; 32(8):650-5. PubMed ID: 18060612
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study.
Chan C; Zambahari R; Kaul U; Lau CP; Whitworth H; Cohen S; Buchbinder M;
Catheter Cardiovasc Interv; 2008 Nov; 72(5):591-600. PubMed ID: 18949772
[TBL] [Abstract][Full Text] [Related]
19. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
20. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
